Randomized phase II study of capecitabine with or without ramucirumab (IMC-1121B) or IMC-18F1 in patients with unresectable, locally advanced or metastatic breast cancer (mBC) previously treated with anthracycline and taxane therapy (CP20-0903/NCT01234402).
L. T. Vahdat
Consultant or Advisory Role - Bristol-Myers Squibb; Eisai
Honoraria - Bristol-Myers Squibb; Eisai
Research Funding - Bristol-Myers Squibb; Celldex; Eisai; ImClone Systems; Novartis
K. Miller
No relevant relationships to disclose
J. A. Sparano
No relevant relationships to disclose
H. Youssoufian
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
J. D. Schwartz
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
S. Nanda
Employment or Leadership Position - ImClone Systems
W. Wang
Employment or Leadership Position - ImClone Systems
L. Abad
Employment or Leadership Position - ImClone Systems
A. Dontabhaktuni
Employment or Leadership Position - ImClone Systems
Stock Ownership - Lilly
M. D. Rutstein
Employment or Leadership Position - ImClone Systems
Stock Ownership - Amgen; Lilly